LEADER 04913nam 22012013a 450 001 9910367755103321 005 20250203235427.0 010 $a9783039213160 010 $a3039213164 024 8 $a10.3390/books978-3-03921-316-0 035 $a(CKB)4100000010106166 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61518 035 $a(ScCtBLL)d2470d31-a268-4c86-a181-af97c3ed37bc 035 $a(OCoLC)1163826911 035 $a(oapen)doab61518 035 $a(EXLCZ)994100000010106166 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aUnconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile$fMaria Contel 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (204 p.) 311 08$a9783039213153 311 08$a3039213156 330 $aFor the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile. 606 $aBiology, life sciences$2bicssc 610 $a?-? stacking 610 $aencapsulation 610 $aoxindolimine-metal complexes 610 $acyclodextrin 610 $aplatinum iodido complexes 610 $adistribution coefficient 610 $aantiproliferative activity 610 $aanticancer agents 610 $ananotubes 610 $aruthenium 610 $aplatinum 610 $aLog kw 610 $ananoparticles 610 $adrug discovery 610 $ametal complex 610 $ametallodrugs 610 $aisatin-derived ligands 610 $aanticancer drug 610 $aupconverting nanoparticles 610 $apyridine benzimidazole 610 $adendrimers 610 $aliposomes 610 $athiophene 610 $aangiogenesis 610 $amicelles 610 $aHSA oxidation 610 $aplatinum(IV) 610 $aimaging 610 $achromatographic lipophilicity parameter 610 $aamidophosphine 610 $acopper and iron chelators in cancer 610 $aLog P 610 $abiomacromolecules 610 $abones 610 $aDNA cleavage 610 $astopped-flow spectroscopy 610 $asilver 610 $aphosphonates 610 $atransmetalation 610 $ametallomics 610 $aMRI 610 $afluorescence quenching 610 $apartition coefficient 610 $agold fingers 610 $aanticancer 610 $aHSA binding 610 $agold 610 $a?0 610 $atargeting 610 $ametastasis 610 $aDNA interaction 610 $aantimigration 610 $acytotoxicity 610 $aHPLC 610 $aruthenium complexes 610 $azinc finger proteins 610 $aGold(III) complexes 610 $aaquaporins 610 $aantiproliferative 610 $aprotein-DNA recognition 610 $aphotoactivation 610 $alipophilicity 610 $acancer 610 $a1-methylcytosine 610 $aPET 615 7$aBiology, life sciences 700 $aContel$b Maria$01328854 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367755103321 996 $aUnconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile$93039033 997 $aUNINA